Establishing and validating a sensitive and accurate LC-MS method for quantifying Lenacapavir (LCV) in rat plasma using D6-LCV as the internal standard. This article presents an overview of the bioanalytical LC-MS method, utilizing a Waters Symmetry C18 column, 150 × 4.6 mm, 3.5 μm and an organic mobile phase comprising acetonitrile and 0.1% formic acid buffer in a ratio of 20:80. The calibration curve for LCV exhibited a linearity range of 5–100 ngml−1 (r2 = 0.9999). Liquid–liquid extraction was employed to recover LCV from rat plasma, resulting in recovery percentages of 98.97%, 99.51%, and 99.49% at three different concentration levels. LCV remained stable during storage under various conditions. Pharmacokinetic analysis yielded key parameters, including a half-life of 120 hours and a time to reach a maximum concentration of 4 hours. LCV and IS were identified using proton adducts in the LC-MS analysis at m/z 969.32/509.15 and 975.28/515.07, respectively, by employing positive mode multiple reaction monitoring. This comprehensive evaluation demonstrates that the method meets stringent criteria for system specificity, linearity, and accuracy, all well within the predefined acceptance limits. Its adaptability for the precise determination of LCV positions it as an invaluable tool in the field of bioanalysis, expanding its clinical utility.
Gope ER, Pottendla S, Yaparthi S. Establishment and validation of LC-MS/MS technique for Lenacapavir quantification in rat plasma, with application to pharmacokinetic assessment. J Appl Pharm Sci. Online First. http://doi.org/10.7324/JAPS.2025.229006
1. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256– 66. doi: https://doi.org/10.1111/HIV.12421
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493–505. doi: https://doi.org/10.1056/NEJMOA1600693
3. Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J Int AIDS Soc. 2019 Oct;22(10):e25408. doi: https://doi.org/10.1002/JIA2.25408
4. Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17(9):1227–38. doi: https://doi.org/10.1080/17425247.2 020.1783233
5. Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022 Jan 1;17(1):15–21. doi: https://doi.org/10.1097/COH.0000000000000713
6. Singh K, Gallazzi F, Hill KJ, Burke DH, Lange MJ, Quinn TP, et al. GS-CA compounds: first-in-class HIV-1 capsid inhibitors covering multiple grounds. Front Microbiol. 2019 Jun 20;10:1227. doi: https://doi.org/10.3389/FMICB.2019.01227
7. Lee NE, Sutherland RK. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus. Curr Opin Infect Dis. 2023 Feb 1;36(1):15–9. doi: https://doi.org/10.1097/QCO.0000000000000896
8. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Aug;584(7822):614–8. doi: https://doi.org/10.1038/S41586-020-2443-1
9. Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022 May 12;386(19):1793– 803. doi: https://doi.org/10.1056/NEJMOA2115542
10. Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023 Feb 16;14:1133407. doi: https://doi.org/10.3389/FMICB.2023.1133407
11. West RE 3rd, Oberly PJ, Riddler SA, Nolin TD, Devanathan AS. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: application to therapeutic monitoring. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Oct 15;1230:123905. doi: https://doi.org/10.1016/J.JCHROMB.2023.123905
Year
Month